Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Liabilities and Shareholders Equity (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Liabilities and Shareholders Equity for 10 consecutive years, with $54.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Liabilities and Shareholders Equity fell 59.92% year-over-year to $54.2 million, compared with a TTM value of $304.5 million through Sep 2025, down 52.05%, and an annual FY2024 reading of $110.5 million, down 39.39% over the prior year.
  • Liabilities and Shareholders Equity was $54.2 million for Q3 2025 at Spero Therapeutics, down from $62.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $182.4 million in Q4 2023 and bottomed at $54.2 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $117.7 million, with a median of $119.6 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 66.11% in 2023, then crashed 59.92% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $171.1 million in 2021, then decreased by 27.05% to $124.8 million in 2022, then skyrocketed by 46.14% to $182.4 million in 2023, then crashed by 39.39% to $110.5 million in 2024, then crashed by 51.0% to $54.2 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for SPRO at $54.2 million in Q3 2025, $62.1 million in Q2 2025, and $77.7 million in Q1 2025.